![Martine Zimmermann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martine Zimmermann
Directeur/Membre du Conseil chez
CANDEL THERAPEUTICS, INC.
Fortune : 1 M $ au 30/09/2026
Profil
Dr. Martine Zimmermann is an Independent Director at Candel Therapeutics, Inc., an Independent Director at Ligand Pharmaceuticals, Inc. and an EVP-Regulatory Affairs & Quality Assurance at Inventiva SA. She is on the Board of Directors at Candel Therapeutics, Inc. and Ligand Pharmaceuticals, Inc. Dr. Zimmermann was previously employed as a SVP, Head-Regulatory Affairs, R&D Quality by Ipsen Biopharmaceuticals, Inc. and a Senior VP & Head-Global Regulatory Affairs by Alexion Pharmaceuticals, Inc. She also served on the board at Caelum Biosciences, Inc. She received her doctorate degree from the University of Strasbourg and a doctorate degree from Louis Pasteur University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/09/2026 | 3 782 ( 0,02 % ) | 1 M $ | 30/09/2026 | |
| 08/09/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
Postes actifs de Martine Zimmermann
| Sociétés | Poste | Début |
|---|---|---|
| INVENTIVA | Conseiller Juridique Général | 09/07/2025 |
| LIGAND PHARMACEUTICALS INCORPORATED | Directeur/Membre du Conseil | 26/09/2023 |
| CANDEL THERAPEUTICS, INC. | Directeur/Membre du Conseil | 08/09/2026 |
Anciens postes connus de Martine Zimmermann
| Sociétés | Poste | Fin |
|---|---|---|
Ipsen Biopharmaceuticals, Inc.
 Ipsen Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | Conseiller Juridique Général | 01/08/2025 |
| ALEXION PHARMACEUTICALS, INC. | Conseiller Juridique Général | 01/02/2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that develops treatments for AL amyloidosis, rare and life-threatening hematologic disorders | Directeur/Membre du Conseil | 01/01/2021 |
Formation de Martine Zimmermann
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
67
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Ligand Pharmaceuticals, Inc.
 Ligand Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and sells drug development technologies | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
University of Strasbourg
 University of Strasbourg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Candel Therapeutics, Inc.
 Candel Therapeutics, Inc. BiotechnologyHealth Technology Develops and distributes immunotherapies for the treatment of cancer | Health Technology |
Ipsen Biopharmaceuticals, Inc.
Ipsen Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | Health Technology |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that develops treatments for AL amyloidosis, rare and life-threatening hematologic disorders | Health Technology |
Louis Pasteur University
 Louis Pasteur University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
